Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013, Article ID 382434, 5 pages
http://dx.doi.org/10.1155/2013/382434
Research Article

The Role of Clomipramine in Potentiating the Teratogenic Effects of Caffeine in Pregnant Rats: A Histopathological Study

1Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Keshavarz Boulevard, Tehran 1417613151, Iran
2Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613146, Iran
3General Physician, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613110, Iran
4Department of Veterinary Sciences, University of Pisa, San Piero a Grado, 56122 Pisa, Italy

Received 10 August 2013; Accepted 27 September 2013

Academic Editors: B. Bar-Oz, T. Nagai, and Y. Shigeri

Copyright © 2013 Vahid Nikoui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. G. Newman, “The thalidomide syndrome: risks of exposure and spectrum of malformations,” Clinics in Perinatology, vol. 13, no. 3, pp. 555–573, 1986. View at Google Scholar · View at Scopus
  2. D. F. Swaab and M. Mirmiran, “Functional teratogenic effects of chemicals on the developing brain,” Monographs in Neural Sciences, vol. 12, pp. 45–57, 1986. View at Google Scholar · View at Scopus
  3. M. Tatsumi, K. Groshan, R. D. Blakely, and E. Richelson, “Pharmacological profile of antidepressants and related compounds at human monoamine transporters,” European Journal of Pharmacology, vol. 340, no. 2-3, pp. 249–258, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. P. K. Gillman, “Tricyclic antidepressant pharmacology and therapeutic drug interactions updated,” British Journal of Pharmacology, vol. 151, no. 6, pp. 737–748, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. U. Busto, R. Bendayan, and E. M. Sellers, “Clinical pharmacokinetics of non-opiate abused drugs,” Clinical Pharmacokinetics, vol. 16, no. 1, pp. 1–26, 1989. View at Google Scholar · View at Scopus
  6. P. F. Brain, J. S. Ajarem, and V. V. Petkov, “The application of ethopharmacological techniques to behavioural teratology: preliminary investigations,” Acta Physiologica et Pharmacologica Bulgarica, vol. 12, no. 4, pp. 3–11, 1986. View at Google Scholar · View at Scopus
  7. W. A. Daniel, M. Kot, and J. Wójcikowski, “Effects of classic and newer antidepressants on the oxidation pathways of caffeine in rat liver. In vitro study,” Polish Journal of Pharmacology, vol. 55, no. 6, pp. 1045–1053, 2003. View at Google Scholar · View at Scopus
  8. R. N. Hines, J. Adams, G. M. Buck et al., “NTP-CERHR expert panel report on the reproductive and developmental toxicity of fluoxetine,” Birth Defects Research B, vol. 71, no. 4, pp. 193–280, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. T. R. Einarson and A. Einarson, “Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies,” Pharmacoepidemiology and Drug Safety, vol. 14, no. 12, pp. 823–827, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Hallberg and V. Sjöblom, “The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects,” Journal of Clinical Psychopharmacology, vol. 25, no. 1, pp. 59–73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Einarson and G. Koren, “Motherisk update: new antidepressants in pregnancy,” Canadian Family Physician, vol. 50, pp. 227–229, 2004. View at Google Scholar · View at Scopus
  12. M. M. Iqbal, “Effects of antidepressants during pregnancy and lactation,” Annals of Clinical Psychiatry, vol. 11, no. 4, pp. 237–256, 1999. View at Google Scholar · View at Scopus
  13. G. Z. Ostergaard and S. E. Pedersen, “Neonatal effects of maternal clomipramine treatment,” Pediatrics, vol. 69, no. 2, pp. 233–234, 1982. View at Google Scholar · View at Scopus
  14. X. Weng, R. Odouli, and D. Li, “Maternal caffeine consumption during pregnancy and the risk of miscarriage: a prospective cohort study,” American Journal of Obstetrics and Gynecology, vol. 198, no. 3, pp. 279.e1–279.e8, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. C. Tucker, “Benzodiazepines and the developing rat: a critical review,” Neuroscience and Biobehavioral Reviews, vol. 9, no. 1, pp. 101–111, 1985. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Takzare, M. Hosseini, A. Bakhtiarian, A. Takzare, and P. Habibi, “The teratogenic effects of flurazepam intake during organogenesis of the rat fetus,” Toxicology Mechanisms and Methods, vol. 18, no. 9, pp. 711–716, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Dlugosz and M. B. Bracken, “Reproductive effects of caffeine: a review and theoretical analysis,” Epidemiologic Reviews, vol. 14, pp. 83–100, 1992. View at Google Scholar · View at Scopus
  18. M. Karlsson, B. R. Danielsson, M. F. Nilsson, C. Danielsson, and W. S. Webster, “New proposals for testing drugs with IKr-blocking activity to determine their teratogenic potential,” Current Pharmaceutical Design, vol. 13, no. 29, pp. 2979–2988, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J. A. Carrillo and J. Benitez, “Clinically significant pharmacokinetic interactions between dietary caffeine and medications,” Clinical Pharmacokinetics, vol. 39, no. 2, pp. 127–153, 2000. View at Google Scholar · View at Scopus
  20. G. D. Anderson, “Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach,” Clinical Pharmacokinetics, vol. 44, no. 10, pp. 989–1008, 2005. View at Publisher · View at Google Scholar · View at Scopus